Open AccessPreferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments
Author(s) -
Ethel D. Weld,
Jacqueline Astemborski,
Gregory D. Kirk,
Mark S. Sulkowski,
Stephanie Katz,
Richard E. Rothman,
Sunil S. Solomon,
Gail Matthews,
YuHsiang Hsieh,
Malvika Verma,
Giovanni Traverso,
Susan Swindells,
Andrew Owen,
Jordan J. Feld,
Charles Flexner,
Shruti H. Mehta,
David L. Thomas
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab913
Subject(s) - medicine , pill , hepatitis c virus , hepatitis c , implant , surgery , virus , immunology , pharmacology
Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-acting HCV treatment.